Legend Biotech Corporation (LEGN) Balance Sheet

This deleveraging trend, occurring alongside a significant expansion in the asset base, suggests the company is funding its growth primarily through equity and operational cash flows rather than incremental borrowing. The improving leverage profile provides greater financial flexibility to absorb the ongoing negative free cash flow and capital expenditure requirements associated with manufacturing scale-up.

The robust cash position, representing over 37% of total assets, appears sufficient to fund near-term operations and the capital-intensive manufacturing build-out without immediate need for external financing. However, the declining trend in the current ratio warrants monitoring, as it reflects the conversion of liquid assets into longer-term productive capacity like PPE.

This pronounced increase in PPE aligns with the reported investments in manufacturing capacity and suggests the company is internalizing more of the complex CAR-T production process. The elimination of goodwill, which stood at $169.5M in 2024Q1, indicates a write-down or divestiture, removing a potential future impairment risk from the balance sheet.

The large and stable negative retained earnings figure underscores that the company has not yet generated sufficient cumulative profit to offset historical R&D and launch investments. The equity base's health is therefore contingent on continued access to capital markets or the partnership with Janssen, as organic profit generation is still in its nascent stages.